Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Involvement of prostacyclin synthase in high-fat-diet-induced obesity.

Sasaki Y., Kuwata H., Akatsu M., Yamakawa Y., Ochiai T., Yoda E.

Animal Study on Type 2 Diabetes, published in Prostaglandins Other Lipid Mediat (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Prostaglandins Other Lipid Mediat (2020)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
33383181
DOI
10.1016/j.prostaglandins.2020.106523

Abstract (original English)

Prostacyclin (PGI 2 ) synthase (PGIS) functions downstream of inducible cyclooxygenase COX-2 in the PGI 2 biosynthetic pathway. Although COX-2 and PGI 2 receptor (IP) are known to be involved in adipogenesis and obesity, the involvement of PGIS has not been fully elucidated. In this study, we examined the role of PGIS in adiposity by using PGIS-deficient mice. Although PGIS deficiency did not affect in vitro adipocyte differentiation, when fed a high-fat diet (HFD), PGIS knockout (KO) mice showed reductions in both body weight gain and epididymal fat mass relative to wild-type (WT) mice. PGIS deficiency might reduce HFD-induced obesity by suppressing PGI 2 production. We further found that additional gene deletion of microsomal prostaglandin (PG) E synthase-1 (mPGES-1), one of the other PG terminal synthases that also functions downstream of COX-2, emphasized the metabolic phenotypes of PGIS-deficient mice. More marked reduction in obesity and improved insulin resistance were observed in PGIS/mPGES-1 double KO (DKO) mice. Since an additive increase in PGF 2α level in epididymal fat was observed in DKO mice, mPGES-1 deficiency might affect adiposity by enhancing the production of PGF 2α . Our immunohistochemical analysis further revealed that in adipose tissues, PGIS was expressed in vascular and stromal cells but not in adipocytes. These results suggested that PGI 2 produced fr

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMaleMiceAdipocytesAdipose TissueAdiposityCytochrome P-450 Enzyme SystemDiet, High-FatEpoprostenolInsulin Resistance

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research